ANI Pharmaceuticals Inc (ANIP)
61.43
-2.34
(-3.67%)
USD |
NASDAQ |
May 17, 16:00
61.45
+0.02
(+0.03%)
After-Hours: 20:00
ANI Pharmaceuticals Enterprise Value: 1.360B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.360B |
| May 16, 2024 | 1.409B |
| May 15, 2024 | 1.431B |
| May 14, 2024 | 1.456B |
| May 13, 2024 | 1.484B |
| May 10, 2024 | 1.498B |
| May 09, 2024 | 1.453B |
| May 08, 2024 | 1.448B |
| May 07, 2024 | 1.471B |
| May 06, 2024 | 1.484B |
| May 03, 2024 | 1.482B |
| May 02, 2024 | 1.480B |
| May 01, 2024 | 1.468B |
| April 30, 2024 | 1.457B |
| April 29, 2024 | 1.446B |
| April 26, 2024 | 1.443B |
| April 25, 2024 | 1.435B |
| April 24, 2024 | 1.445B |
| April 23, 2024 | 1.460B |
| April 22, 2024 | 1.449B |
| April 19, 2024 | 1.446B |
| April 18, 2024 | 1.427B |
| April 17, 2024 | 1.446B |
| April 16, 2024 | 1.448B |
| April 15, 2024 | 1.463B |
| Date | Value |
|---|---|
| April 12, 2024 | 1.475B |
| April 11, 2024 | 1.501B |
| April 10, 2024 | 1.477B |
| April 09, 2024 | 1.479B |
| April 08, 2024 | 1.490B |
| April 05, 2024 | 1.491B |
| April 04, 2024 | 1.497B |
| April 03, 2024 | 1.483B |
| April 02, 2024 | 1.472B |
| April 01, 2024 | 1.496B |
| March 31, 2024 | 1.522B |
| March 28, 2024 | 1.540B |
| March 27, 2024 | 1.552B |
| March 26, 2024 | 1.550B |
| March 25, 2024 | 1.551B |
| March 22, 2024 | 1.550B |
| March 21, 2024 | 1.545B |
| March 20, 2024 | 1.521B |
| March 19, 2024 | 1.515B |
| March 18, 2024 | 1.509B |
| March 15, 2024 | 1.475B |
| March 14, 2024 | 1.481B |
| March 13, 2024 | 1.485B |
| March 12, 2024 | 1.491B |
| March 11, 2024 | 1.483B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
462.56M
Minimum
Nov 06 2020
1.552B
Maximum
Mar 27 2024
879.07M
Average
867.13M
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals Inc | 1.235B |
| ADMA Biologics Inc | 2.220B |
| Annovis Bio Inc | 89.70M |
| United Therapeutics Corp | 10.06B |
| Allogene Therapeutics Inc | 193.47M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 18.21M |
| Revenue (Quarterly) | 137.43M |
| Total Expenses (Quarterly) | 122.38M |
| EPS Diluted (Quarterly) | 0.82 |
| Gross Profit Margin (Quarterly) | 64.23% |
| Profit Margin (Quarterly) | 13.25% |
| Earnings Yield | 2.57% |
| Operating Earnings Yield | 4.52% |
| Normalized Earnings Yield | 1.692 |